{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-09-29",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "0310-1248",
      "generic_name": "osimertinib",
      "labeler_name": "AstraZeneca Pharmaceuticals LP",
      "brand_name": "TAGRISSO",
      "active_ingredients": [
        {
          "name": "OSIMERTINIB",
          "strength": "40 mg/1"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "0310-1248-30",
          "description": "30 TABLET, FILM COATED in 1 BOTTLE (0310-1248-30)",
          "marketing_start_date": "20250220",
          "sample": false
        }
      ],
      "listing_expiration_date": "20271231",
      "openfda": {},
      "marketing_category": "NDA",
      "dosage_form": "TABLET, FILM COATED",
      "spl_id": "bc71de23-ee63-49b7-8b0e-97e5e8a52d05",
      "product_type": "HUMAN PRESCRIPTION DRUG",
      "route": [
        "ORAL"
      ],
      "marketing_start_date": "20151113",
      "product_id": "0310-1248_bc71de23-ee63-49b7-8b0e-97e5e8a52d05",
      "application_number": "NDA208065",
      "brand_name_base": "TAGRISSO",
      "pharm_class": [
        "Breast Cancer Resistance Protein Inhibitors [MoA]",
        "Cytochrome P450 1A2 Inducers [MoA]",
        "Cytochrome P450 3A Inhibitors [MoA]",
        "Cytochrome P450 3A4 Inducers [MoA]",
        "Kinase Inhibitor [EPC]",
        "Kinase Inhibitors [MoA]"
      ]
    }
  ]
}